{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:49:06Z","timestamp":1761767346063,"version":"3.37.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s41669-024-00504-8","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T03:37:02Z","timestamp":1720237022000},"page":"715-725","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata"],"prefix":"10.1007","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7597-6556","authenticated-orcid":false,"given":"Andrew","family":"Lloyd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Aggio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caleb","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest H.","family":"Law","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,6]]},"reference":[{"key":"504_CR1","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res [Internet]. 2011;20:1727\u201336.","journal-title":"Qual Life Res [Internet]."},{"key":"504_CR2","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s10198-020-01195-8","volume":"21","author":"M Kennedy-Martin","year":"2020","unstructured":"Kennedy-Martin M, Slaap B, Herdman M, van Reenen M, Kennedy-Martin T, Greiner W, et al. Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. Eur J Health Econ [Internet]. 2020;21:1245\u201357.","journal-title":"Eur J Health Econ [Internet]."},{"key":"504_CR3","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1007\/s11136-016-1375-6","volume":"25","author":"F Rencz","year":"2016","unstructured":"Rencz F, Gul\u00e1csi L, Drummond M, Golicki D, Prevolnik Rupel V, Simon J, et al. EQ-5D in Central and Eastern Europe: 2000\u20132015. Qual Life Res [Internet]. 2016;25:2693\u2013710. https:\/\/doi.org\/10.1007\/s11136-016-1375-6.","journal-title":"Qual Life Res [Internet]"},{"key":"504_CR4","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1177\/0272989X16638312","volume":"36","author":"AH Briggs","year":"2016","unstructured":"Briggs AH, Parfrey PS, Khan N, Tseng S, Dehmel B, Kubo Y, et al. Analyzing health-related quality of life in the EVOLVE trial: the joint impact of treatment and clinical events. Med Decis Making [Internet]. 2016;36:965\u201372.","journal-title":"Med Decis Making [Internet]."},{"key":"504_CR5","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/0272989X0202200412","volume":"22","author":"P Clarke","year":"2016","unstructured":"Clarke P, Gray A, Holman R. Estimating utility values for health states of Type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making [Internet]. 2016;22:340\u20139. https:\/\/doi.org\/10.1177\/0272989X0202200412.","journal-title":"Med Decis Making [Internet]."},{"key":"504_CR6","doi-asserted-by":"crossref","unstructured":"Briggs AH, Glick HA, Lozano-Ortega G, Spencer M, Calverley PMA, Jones PW, et al. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. Eur Respir J [Internet]. 2010;35:532\u20139. https:\/\/erj.ersjournals.com\/content\/35\/3\/532","DOI":"10.1183\/09031936.00153108"},{"key":"504_CR7","doi-asserted-by":"crossref","unstructured":"Herdman M, Kerr C, Pavesi M, Garside J, Lloyd A, Cubi-Molla P, et al. Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed\/refractory mantle cell lymphoma, and comparison to EQ-5D-5L. J Patient Rep Outcomes [Internet]. 2020;4.","DOI":"10.1186\/s41687-020-0185-3"},{"key":"504_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40273-017-0546-9","volume":"35","author":"D Rowen","year":"2017","unstructured":"Rowen D, Brazier J, Ara R, Azzabi Zouraq I. The role of condition-specific preference-based measures in health technology assessment. PharmacoEconomics [Internet]. 2017;35:33\u201341. https:\/\/doi.org\/10.1007\/s40273-017-0546-9.","journal-title":"PharmacoEconomics [Internet]."},{"key":"504_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1177\/0272989X19847983","volume":"39","author":"M Hoogendoorn","year":"2019","unstructured":"Hoogendoorn M, Oppe M, Boland MRS, Goossens LMA, Stolk EA, Rutten-van M\u00f6lken MPMH. Exploring the impact of adding a respiratory dimension to the EQ-5D-5L. Medical Decision Making [Internet]. 2019;39:393.","journal-title":"Medical Decision Making [Internet]."},{"key":"504_CR10","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.jval.2013.10.003","volume":"16","author":"P Swinburn","year":"2013","unstructured":"Swinburn P, Lloyd A, Boye KS, Edson-Heredia E, Bowman L, Janssen B. Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK. Value Health [Internet]. 2013;16:1156\u201362.","journal-title":"Value Health [Internet]."},{"key":"504_CR11","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1007\/s11136-022-03141-y","volume":"31","author":"F Rencz","year":"2022","unstructured":"Rencz F, Mukuria C, Bat\u00f3 A, Po\u00f3r AK, Finch AP. A qualitative investigation of the relevance of skin irritation and self-confidence bolt-ons and their conceptual overlap with the EQ-5D in patients with psoriasis. Qual Life Res [Internet]. 2022;31:3049\u201360.","journal-title":"Qual Life Res [Internet]."},{"key":"504_CR12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jval.2014.09.004","volume":"18","author":"Y Yang","year":"2015","unstructured":"Yang Y, Rowen D, Brazier J, Tsuchiya A, Young T, Longworth L. An exploratory study to test the impact on three \u2018bolt-on\u2019 items to the EQ-5D. Value Health [Internet]. 2015;18:52\u201360.","journal-title":"Value Health [Internet]."},{"key":"504_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.autrev.2014.10.014","volume":"14","author":"N Islam","year":"2015","unstructured":"Islam N, Leung PSC, Huntley AC, Eric GM. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015;14:81\u20139.","journal-title":"Autoimmun Rev"},{"key":"504_CR14","unstructured":"Alopecia areata\u2014Level 3 cause|Institute for Health Metrics and Evaluation [Internet]. [cited 2024 Jan 9]. https:\/\/www.healthdata.org\/results\/gbd_summaries\/2019\/alopecia-areata-level-3-cause."},{"key":"504_CR15","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"CH Pratt","year":"2017","unstructured":"Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers [Internet]. 2017;3:17011.","journal-title":"Nat Rev Dis Primers [Internet]."},{"key":"504_CR16","doi-asserted-by":"crossref","unstructured":"Liu LY, King BA, Craiglow BG. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): a systematic review. J Am Acad Dermatol. Mosby Inc.; 2016. p. 806-812.e3.","DOI":"10.1016\/j.jaad.2016.04.035"},{"key":"504_CR17","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/bjd.14497","volume":"175","author":"F Rencz","year":"2016","unstructured":"Rencz F, Gul\u00e1csi L, P\u00e9ntek M, Wikonk\u00e1l N, Baji P, Brodszky V. Alopecia areata and health-related quality of life: a systematic review and meta-analysis. Br J Dermatol [Internet]. 2016;175:561\u201371. https:\/\/doi.org\/10.1111\/bjd.14497.","journal-title":"Br J Dermatol [Internet]."},{"key":"504_CR18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s13555-020-00477-6","volume":"11","author":"J Macey","year":"2021","unstructured":"Macey J, Kitchen H, Aldhouse NVJ, Burge RT, Edson-Heredia E, McCollam JS, et al. Dermatologist and patient perceptions of treatment success in alopecia areata and evaluation of clinical outcome assessments in japan. Dermatol Ther (Heidelb) [Internet]. 2021;11:433\u201347. https:\/\/doi.org\/10.1007\/s13555-020-00477-6.","journal-title":"Dermatol Ther (Heidelb) [Internet]."},{"key":"504_CR19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13555-021-00508-w","volume":"11","author":"R Winnette","year":"2021","unstructured":"Winnette R, Martin S, Harris N, Deal LS. Development of the alopecia areata patient priority outcomes instrument: a qualitative study. Dermatol Ther (Heidelb) [Internet]. 2021;11:599\u2013613. https:\/\/doi.org\/10.1007\/s13555-021-00508-w.","journal-title":"Dermatol Ther (Heidelb) [Internet]."},{"key":"504_CR20","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/bjd.17463","volume":"180","author":"L Davey","year":"2019","unstructured":"Davey L, Clarke V, Jenkinson E. Living with alopecia areata: an online qualitative survey study. Br J Dermatol. 2019;180:1377\u201389.","journal-title":"Br J Dermatol"},{"key":"504_CR21","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/jdv.13520","volume":"30","author":"S Jankovic","year":"2016","unstructured":"Jankovic S, Peric J, Maksimovic N, Cirkovic A, Marinkovic J, Jankovic J, et al. Quality of life in patients with alopecia areata: a hospital-based cross-sectional study. J Eur Acad Dermatol Venereol [Internet]. 2016;30:840\u20136. https:\/\/doi.org\/10.1111\/jdv.13520.","journal-title":"J Eur Acad Dermatol Venereol [Internet]."},{"key":"504_CR22","doi-asserted-by":"crossref","unstructured":"Mesinkovska N, King B, Mirmirani P, Ko J, Cassella J. Burden of illness in alopecia areata: a cross-sectional online survey study. J Investig Dermatol Symp Proc [Internet]. 2020;20:S62\u20138. http:\/\/www.jidsponline.org\/article\/S1087002420300174\/fulltext. Accessed 28 Oct 2021.","DOI":"10.1016\/j.jisp.2020.05.007"},{"key":"504_CR23","doi-asserted-by":"crossref","unstructured":"Toussi A, Barton VR, Le ST, Agbai ON, Kiuru M. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review. J Am Acad Dermatol [Internet]. 2021;85:162\u201375. http:\/\/www.jaad.org\/article\/S0190962220311440\/fulltext.","DOI":"10.1016\/j.jaad.2020.06.047"},{"key":"504_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/983804","volume":"2013","author":"J Masmoudi","year":"2013","unstructured":"Masmoudi J, Sellami R, Ouali U, Mnif L, Feki I, Amouri M, et al. Quality of life in alopecia areata: a sample of Tunisian patients. Dermatol Res Pract. 2013;2013:1.","journal-title":"Dermatol Res Pract"},{"key":"504_CR25","unstructured":"A phase 3 study to evaluate the efficacy and safety of CTP-543 in adult patients with moderate to severe alopecia areata (THRIVE-AA2)\u2014Full Text View\u2014ClinicalTrials.gov [Internet]. [cited 2023 Mar 2]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04797650."},{"key":"504_CR26","unstructured":"A phase 3 study to evaluate the efficacy and safety of ctp-543 in adult patients with moderate to severe alopecia areata (THRIVE-AA1) \u2014Full Text View\u2014ClinicalTrials.gov [Internet]. [cited 2023 Mar 2]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04518995."},{"key":"504_CR27","unstructured":"A study of baricitinib (LY3009104) in adults with severe or very severe alopecia areata\u2014Full Text View\u2014ClinicalTrials.gov [Internet]. [cited 2023 Mar 2]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03899259."},{"key":"504_CR28","unstructured":"A study of baricitinib (LY3009104) in participants with severe or very severe alopecia areata\u2014Full Text View\u2014ClinicalTrials.gov [Internet]. [cited 2023 Mar 2]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03570749."},{"key":"504_CR29","unstructured":"PF-06651600 for the treatment of alopecia areata\u2014Full Text View\u2014ClinicalTrials.gov [Internet]. [cited 2023 Mar 2]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03732807."},{"key":"504_CR30","unstructured":"National Institute for Health and Care Excellence. Draft guidance consultation: Baricitinib for treating severe alopecia areata [Internet]. [cited 2023 May 5]. https:\/\/www.nice.org.uk\/guidance\/gid-ta10941\/documents\/129."},{"key":"504_CR31","unstructured":"Baricitinib for treating severe alopecia areata: Public Committee slides [Internet]. [cited 2023 May 5]. https:\/\/www.nice.org.uk\/guidance\/gid-ta10941\/documents\/1."},{"key":"504_CR32","unstructured":"Baricitinib not recommended by NICE for routine commissioning in the NHS | Alopecia UK [Internet]. [cited 2023 May 5]. https:\/\/www.alopecia.org.uk\/news\/baricitinib-not-recommended-by-nice-for-routine-commissioning-in-the-nhs."},{"key":"504_CR33","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1007\/s11136-017-1699-x","volume":"26","author":"AK Po\u00f3r","year":"2017","unstructured":"Po\u00f3r AK, Rencz F, Brodszky V, Gul\u00e1csi L, Beretzky Z, Hidv\u00e9gi B, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. Qual Life Res [Internet]. 2017;26:3409\u201319. https:\/\/doi.org\/10.1007\/s11136-017-1699-x.","journal-title":"Qual Life Res [Internet]."},{"key":"504_CR34","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s11136-020-02732-x","volume":"30","author":"A Bat\u00f3","year":"2021","unstructured":"Bat\u00f3 A, Brodszky V, Gergely LH, G\u00e1sp\u00e1r K, Wikonk\u00e1l N, Kiny\u00f3 \u00c1, et al. The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa. Qual Life Res [Internet]. 2021;30:1477\u201390. https:\/\/doi.org\/10.1007\/s11136-020-02732-x.","journal-title":"Qual Life Res [Internet]."},{"key":"504_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10198-022-01460-y","volume":"24","author":"K Koszor\u00fa","year":"2023","unstructured":"Koszor\u00fa K, Hajdu K, Brodszky V, Bat\u00f3 A, Gergely LH, Kov\u00e1cs A, et al. Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L descriptive systems and utilities in atopic dermatitis. Eur J Health Econ [Internet]. 2023;24:139\u201352. https:\/\/doi.org\/10.1007\/s10198-022-01460-y.","journal-title":"Eur J Health Econ [Internet]."},{"key":"504_CR36","unstructured":"Baricitinib for treating moderate to severe atopic dermatitis Technology appraisal guidance. 2021 [cited 2022 Oct 26]; http:\/\/www.nice.org.uk\/guidance\/ta681."},{"key":"504_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s13555-021-00648-z","volume":"12","author":"KW Wyrwich","year":"2021","unstructured":"Wyrwich KW, Winnette R, Bender R, Gandhi K, Williams N, Harris N, et al. Validation of the alopecia areata patient priority outcomes (AAPPO) questionnaire in adults and adolescents with alopecia areata. Dermatol Ther (Heidelb) [Internet]. 2021;12:149\u201366. https:\/\/doi.org\/10.1007\/s13555-021-00648-z.","journal-title":"Dermatol Ther (Heidelb) [Internet]."},{"key":"504_CR38","unstructured":"Ware J, Kosinski M, Bjorner J, Turner-Bowker D, Gandek B, Maruish M. User\u2019s Manual for the SF-36v2 Health Survey. Ware J, Kosinski M, Bjorner J, Turner-Bowker D, Gandek B, Maruish M. Development. User\u2019s Manual for the SF-36v2\u00ae Health Survey. Lincoln (RI): QualityMetric Incorporated; 2007. Lincoln: QualityMetric Incorporated; 2007."},{"key":"504_CR39","doi-asserted-by":"crossref","unstructured":"Olsen E, Hordinsky M, McDonald-Hull S, Price V, Roberts J, Shapiro J, et al. Alopecia areata investigational assessment guidelines. J Am Acad Dermatol [Internet]. 1999;40:242\u20136. http:\/\/www.jaad.org\/article\/S0190962299701957\/fulltext.","DOI":"10.1016\/S0190-9622(99)70195-7"},{"key":"504_CR40","first-page":"1262","volume":"145","author":"BE Strober","year":"2009","unstructured":"Strober BE, Menon K, McMichael A, Hordinsky M, Krueger G, Panko J, et al. Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study. Arch Dermatol [Internet]. 2009;145:1262\u20136.","journal-title":"Arch Dermatol [Internet]."},{"key":"504_CR41","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/hec.4487","volume":"31","author":"M Hern\u00e1ndez-Alava","year":"2022","unstructured":"Hern\u00e1ndez-Alava M, Pudney S. Mapping between EQ-5D-3L and EQ-5D-5L: a survey experiment on the validity of multi-instrument data. Health Econ [Internet]. 2022;31:923\u201339. https:\/\/doi.org\/10.1002\/hec.4487.","journal-title":"Health Econ [Internet]."},{"key":"504_CR42","doi-asserted-by":"publisher","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. Statistical Power Analysis for the Behavioral Sciences [Internet]. 2013 [cited 2022 Oct 26]; https:\/\/doi.org\/10.4324\/9780203771587","DOI":"10.4324\/9780203771587"},{"key":"504_CR43","doi-asserted-by":"publisher","first-page":"18053","DOI":"10.3389\/fpsyg.2012.00055","volume":"3","author":"DB Flora","year":"2012","unstructured":"Flora DB, LaBrish C, Chalmers RP. Old and new ideas for data screening and assumption testing for exploratory and confirmatory factor analysis. Front Psychol. 2012;3:18053.","journal-title":"Front Psychol"},{"key":"504_CR44","doi-asserted-by":"crossref","unstructured":"Burge RT, Anderson P, Austin J, Piercy J, Manuel L, Edson-Heredia E, et al. 26158 The patient-reported burden of alopecia areata by current severity: A real-world study in the US. J Am Acad Dermatol [Internet]. 2021;85:AB86. http:\/\/www.jaad.org\/article\/S0190962221014729\/fulltext.","DOI":"10.1016\/j.jaad.2021.06.368"},{"key":"504_CR45","unstructured":"Brazier J, Rowen D. NICE DSU Technical Support Document 11: alternatives to EQ-5D for Generating health state utility values. NICE DSU technical support document 11: alternatives to EQ-5D for generating health state utility values [Internet]. 2011."},{"key":"504_CR46","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jval.2022.01.009","volume":"25","author":"J Brazier","year":"2022","unstructured":"Brazier J, Peasgood T, Mukuria C, Marten O, Kreimeier S, Luo N, et al. The EQ-HWB: overview of the development of a measure of health and wellbeing and key results. Value Health. 2022;25:482\u201391.","journal-title":"Value Health."},{"key":"504_CR47","unstructured":"ReQoL TM Recovering quality of life."},{"key":"504_CR48","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1007\/s13555-023-01057-0","volume":"13","author":"S Va\u00f1\u00f3-Galv\u00e1n","year":"2023","unstructured":"Va\u00f1\u00f3-Galv\u00e1n S, Blume-Peytavi U, Farrant P, Reygagne P, Johansson E, Reed C, et al. Physician- and patient-reported severity and quality of life impact of alopecia areata: results from a real-world survey in five european countries. Dermatol Ther (Heidelb) [Internet]. 2023;13:3121.","journal-title":"Dermatol Ther (Heidelb) [Internet]."}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00504-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-024-00504-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00504-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T08:09:25Z","timestamp":1724918965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-024-00504-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,6]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["504"],"URL":"https:\/\/doi.org\/10.1007\/s41669-024-00504-8","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"type":"print","value":"2509-4262"},{"type":"electronic","value":"2509-4254"}],"subject":[],"published":{"date-parts":[[2024,7,6]]},"assertion":[{"value":"28 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by Pfizer Inc. Acaster Lloyd Consulting Ltd. retained complete control over the statistical analysis of the data and the initial draft of the paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"T.P. (Pfizer Ltd.) and E.H.L. (Pfizer Inc.) are employees of and hold stock or stock options in Pfizer. E.H.L. is a member of the EuroQol group, which is responsible for licensing the EQ-5D. D.A. and C.D. are employees of Acaster Lloyd Consulting Ltd. A.L. is an employee and shareholder of Acaster Lloyd Consulting Ltd and a board member of the EuroQol group. Acaster Lloyd Consulting Ltd were commissioned by Pfizer Inc, the study sponsor, to conduct the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Upon request and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See\u00a0\u00a0for more information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Code for data cleaning and analysis in support of the analyses in the manuscript is available upon reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This study is a post hoc analysis of ALLEGRO phase 2b\u20133 clinical trial data. This was a randomised, double-blind, multicentre, phase 2\u20133 trial done at 118 hospitals and clinics in Argentina, Australia, Canada, Chile, China, Colombia, Czech Republic, Germany, Hungary, Japan, Korea, Mexico, Poland, Russia, Spain, Taiwan, the UK and the USA. This protocol was approved by the institutional review boards or ethics committees of the participating institutions. The study was conducted in accordance with the general principles set forth in the International Ethical Guidelines for Biomedical Research Involving Human Subjects (Council for International Organizations of Medical Sciences 2002), ICH Guideline for Good Clinical Practice and the Declaration of Helsinki. Written informed consent to participate was obtained from each patient. Written informed consent to publish the findings was also obtained from each patient.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Concept and design: A.L., D.A., E.H.L., T.P. Acquisition of data: E.H.L, T.P. Analysis and interpretation: A.L., D.A., C.D., E.H.L., T.P. Drafting the manuscript: A.L., D.A., C.D. Critical review of the paper: A.L., D.A., E.H.L., T.P.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}